Collectively, our data illustrate that the activation of the FGF-2-based autocrine loop in GISTs is a potent mechanism modulating GIST responses to KIT inhibition and maintaining resistance to IM. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.